Planning new Trypanosoma cruzi CYP51 inhibitors using QSAR studies.

Pedro Igor Camara de Oliveira, Paulo Henrique de Santana Miranda, Estela Mariana Guimaraes Lourenço, Priscilla Suene de Santana Nogueira Silverio, Euzebio Guimaraes Barbosa

Molecular diversity 2021 Nov

filter terms:

Chagas disease kills over 10,000 people per year, and approximately 8 million people are infected by Trypanosoma cruzi. The reference drug for treatment of the disease, benznidazole, is the same since the 70s. In recent years, many CYP51 inhibitors were tested against this parasite's target. One of them, posaconazole, was even tested in clinical trials that unfortunately were not successful. Nevertheless, there are still many evidences that CYP51 is a great potential target to treat T. cruzi infection. The research for new effective molecules that can cure the chronic phase of the disease is essential. 2D and 3D-quantitative structure activity relationship (QSAR) studies were conducted in this work to create three QSAR models using the chemical structures of 197 published compounds that already went through either in vivo or in vitro tests. After the analysis of the models, new analogues not yet synthesized were suggested here and had their biological activity and synthetic availability assessed. © 2020. Springer Nature Switzerland AG.

Citation

Pedro Igor Camara de Oliveira, Paulo Henrique de Santana Miranda, Estela Mariana Guimaraes Lourenço, Priscilla Suene de Santana Nogueira Silverio, Euzebio Guimaraes Barbosa. Planning new Trypanosoma cruzi CYP51 inhibitors using QSAR studies. Molecular diversity. 2021 Nov;25(4):2219-2235